Rise of Cytomegalovirus Antibodies in an Infectious-mononucleosis-like Syndrome after Transfusion

Kääriäinen, Leevi; Klemola, E; Paloheimo, J.

doi:10.1136/bmj.1.5498.1270

Cited by 239 publications

(50 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In only 1 of 3 reported cases of fatal CMV in previously healthy patients were intranuclear inclusion bodies demonstrated in lung tissue [15,21,22], In patients with other illness, the underlying disease and therapeutic pro cedures influence the prevalence and outcome of CMV. There is evidence that in many of these patients the virus is introduced by transfusions of fresh blood [7,9,14,20], Symptoms usually begin 3-6 weeks later. Our patient was transfused with fresh blood from 4 different donors 6 weeks before onset of the symptoms.…”

Section: Discussionmentioning

confidence: 99%

“…Since then, clini cally apparent CMV in the adult population has been found with increasing frequency [2,11]. The disease is common following immunosuppressive the rapy after organ transplants [3,18], with treatment for acute leukemia or malignant lymphoma [1,5] and after transfusion of blood which had been stored for less than 48 h [9,14]. In patients with malignant disease, CMV of ten is the last of a series of complications and frequently is not recognized before death.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Rapidly Fatal Cytomegalovirus Pneumonia in Hodgkin’s Disease

Mikus¹,

Carrington²,

Gaensler³

1974

Respiration

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Rapidly Fatal Cytomegalovirus Pneumonia in Hodgkin’s Disease

Mikus¹,

Carrington²,

Gaensler³

1974

Respiration

View full text Add to dashboard Cite

show abstract

“…52 This is clearly less than the cost of treatment of CMV disease or CMV prophylaxis with ganciclovir after marrow transplantation, suggesting that prevention of Vol. 1 …”

Section: Cost Analysismentioning

confidence: 99%

Prevention of Transfusion-Associated Cytomegalovirus Infection:Practice Parameter

Przepiorka¹,

Leparc²,

Werch³

et al. 1996

Am J Clin Pathol

View full text Add to dashboard Cite

Cytomegalovirus (CM V) infection has been a recognized complication of transfusions for nearly three decades.' More recently, it has been shown that transfusion-related CMV infections present considerable problems for the immunocompromised patient. 23 The potential morbidity and mortality due to transfusion-related CMV infections in this group of patients are very high. Policies and procedures to prevent the unintentional transmission of this virus are critical. Current strategies consist of screening blood components, leukocyte reduction of blood components, hyperimmune gamma globulin prophylaxis, and viral inactivation. The numbers of patients with temporary or permanent states of immunodeficiency who require CMV-negative blood components are increasing, and this has led to shortages in the supply. CMV-seronegative donors are a minority in the donor Physicians are encouraged to document the reasons for whatever procedure or test they use (whether or not in conformance with this guideline). Physicians should also take care to consider other medical and scientific advances that are available after the date of adoption of this guideline.This practice guideline was developed exclusively for the purposes set forth above and not for use in connection with matters involving reimbursement, credentialing, or utilization review.

show abstract

“…Transfusion-transmitted CMV infections (TT-CMV) were first described by Kääriäinen and co-workers in 1966 [4]. After development of suitable biochemical methods (restriction endonuclease analysis), the molecular evidence for TT-CMV was provided by Tolpin and colleagues in 1985 [5].…”

Section: Introductionmentioning

confidence: 99%

Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?

Ziemann¹,

Hennig²

2013

Transfus Med Hemother

View full text Add to dashboard Cite

Traditionally, leukoreduction and selection of blood products from seronegative donors have been used as alternative strategies to reduce the risk of transfusion-transmitted cytomegalovirus infections (TT-CMV) in atrisk patients. After the introduction of universal leukoreduction for red blood cell and platelet concentrates in Germany, a controversy evolved as to whether the additional selection of blood products from seronegative donors would reduce or even increase the risk of TT-CMV. This review summarizes the current knowledge about CMV infections in blood donors and the implications of this information on the effect of potential transfusion strategies. Even though there are conflicting data about the incidence of TT-CMV remaining after the introduction of leukodepletion, it has been clearly shown that both prevalence and concentration of CMV DNA in peripheral blood are highest in newly seropositive donors. Therefore, avoidance of blood products from these donors is the most important goal of any transfusion strategy. This goal can be reached by: i) selection of blood products from seronegative donors, ii) provision of CMV DNA-negative blood products, or iii) provision of blood from long-term seropositive donors. In cases of suspected TT-CMV, all implicated donors should be investigated carefully to gather further knowledge on which donors confer the lowest risk for TT-CMV.

show abstract

Rise of Cytomegalovirus Antibodies in an Infectious-mononucleosis-like Syndrome after Transfusion

Cited by 239 publications

References 7 publications

Rapidly Fatal Cytomegalovirus Pneumonia in Hodgkin’s Disease

Rapidly Fatal Cytomegalovirus Pneumonia in Hodgkin’s Disease

Prevention of Transfusion-Associated Cytomegalovirus Infection:Practice Parameter

Prevention of Transfusion-Transmitted Cytomegalovirus Infections: Which is the Optimal Strategy?

Contact Info

Product

Resources

About